Generation of an Attenuated Chimeric Bat Influenza A Virus Live-Vaccine Prototype

Abstract

Recurring influenza A virus outbreaks in livestock, particularly in swine and chickens, pose a constant threat to humans. Live attenuated influenza vaccines (LAIVs) might be a potent tool to prevent epizootic outbreaks and the resulting human IAV infections; however, LAIVs have several disadvantages, especially in terms of reassortment with circulating IAVs.

Reassortment incompetent live attenuated and replicon influenza vaccines provide improved protection against influenza in piglets

“…The chimeric bat influenza virus was approved by the Regional Council of Baden-Württemberg, Germany (license number SSI2-UNI.FRK.05.23/05.18/05.22.) and the State Office for Health and Social Affairs of Mecklenburg-Western-Pomerania, Germany (LAGuS3021_4/11.5.17), and was generated as described previously 33 , 66 , 67 . Briefly, the HA coding region of swIAV AI03362 was flanked at the 3′- and 5′-terminal ends by the putative cis -acting terminal packaging sequences from A/little yellow-shouldered bat/Guatemala/164/2009 (H17N10) (nucleotides 1 to 131 for the 3′ noncoding region and nucleotides 1621 to 1784 for the 5′ noncoding region).…”